Literature DB >> 16248845

Oxidative stress: the old enemy in Alzheimer's disease pathophysiology.

Paula I Moreira1, Kazuhiro Honda, Quan Liu, Maria S Santos, Catarina R Oliveira, Gjumrakch Aliev, Akihiko Nunomura, Xiongwei Zhu, Mark A Smith, George Perry.   

Abstract

The complex nature and genesis of oxidative damage in Alzheimer disease can be partly answered by mitochondrial and redox-active metal abnormalities. By releasing high levels of hydrogen peroxide, dysfunctional mitochondria propagate a series of interactions between redox-active metals and oxidative response elements. In the initial phase of disease development, amyloid-beta deposition and hyperphosphorylated tau may function as compensatory responses and downstream adaptations to ensure that neuronal cells do not succumb to oxidative injuries. However, during the progression of the disease, the antioxidant activity of both agents evolves into pro-oxidant activity representing a typical gain-of-function transformation, which can result from an increase in reactive species and a decrease in clearance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248845     DOI: 10.2174/156720505774330537

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  34 in total

Review 1.  Oxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives.

Authors:  W Ying; Z-G Xiong
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Secrets of the lac operon. Glucose hysteresis as a mechanism in dietary restriction, aging and disease.

Authors:  Charles V Mobbs; Jason W Mastaitis; Minhua Zhang; Fumiko Isoda; Hui Cheng; Kelvin Yen
Journal:  Interdiscip Top Gerontol       Date:  2007

Review 3.  Mechanisms underlying caloric restriction and lifespan regulation: implications for vascular aging.

Authors:  Zoltan Ungvari; Cristina Parrado-Fernandez; Anna Csiszar; Rafael de Cabo
Journal:  Circ Res       Date:  2008-03-14       Impact factor: 17.367

4.  Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain.

Authors:  Changxing Shao; Shuling Xiong; Guo-Min Li; Liya Gu; Guogen Mao; William R Markesbery; Mark A Lovell
Journal:  Free Radic Biol Med       Date:  2008-06-11       Impact factor: 7.376

Review 5.  Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Tamar Amit
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

Review 6.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Acridine derivatives inhibit lysozyme aggregation.

Authors:  Zuzana Gazova; Andrea Bellova; Zuzana Daxnerova; Jan Imrich; Pavol Kristian; Jana Tomascikova; Jaroslava Bagelova; Diana Fedunova; Marian Antalik
Journal:  Eur Biophys J       Date:  2008-04-03       Impact factor: 1.733

8.  Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress.

Authors:  Patricia Ferrera; Octavio Mercado-Gómez; Martín Silva-Aguilar; Mahara Valverde; Clorinda Arias
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

9.  Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.

Authors:  Richard A Maki; Vladimir A Tyurin; Robert C Lyon; Ronald L Hamilton; Steven T DeKosky; Valerian E Kagan; Wanda F Reynolds
Journal:  J Biol Chem       Date:  2008-12-05       Impact factor: 5.157

Review 10.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.